Kintara Therapeutics, Inc.
Kintara Therapeutics, Inc. (KTRA) Stock Overview
Explore Kintara Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
KTRA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Kintara Therapeutics, Inc. (KTRA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.13.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.70 and a market capitalization of 12M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Mr. Jeffrey A. Bacha B.Sc., M.B.A.
1
12707 High Bluff Drive, San Diego, CA
2013